Precise Manipulation of Intracellular RNA Using DNA Guides with CRISPR–Cas12
##1. The Lethal Toxicity of Cas13 and the Need for Next-Generation RNA Targeting Platforms To date, the CRISPR‑Cas13 system has been the primary tool studied for direct recognition and cleavage of intracellular RNA. However, Cas13 exhibits a lethal intrinsic toxicity known as “collateral cleavage / bystander effect,” in which, after cutting the target RNA, it indiscriminately destroys surrounding non‑target RNAs. This has been a major obstacle for therapeutic development and precise transcript regulation in human cells. Consequently, the development of a next‑generation RNA‑targeting platform that operates without collateral cleavage and functions stably in vivo has been a long‑standing goal of the genomics medicine community.
##2. Molecular Design of ΨDNA Guides: Converting a DNA‑Cleaving Enzyme into an RNA Regulator The research team discovered a breakthrough that completely reprograms the substrate specificity of Cas12, an enzyme that normally cleaves double‑stranded DNA. Instead of a conventional crRNA guide, they paired Cas12 with a specially designed ΨDNA guide (Psi‑DNA guide). This hybrid guide directs the Cas12 complex to recognize single‑stranded RNA sequences inside cells with high precision. By fine‑tuning the guide length and spacer architecture, they switched the enzyme’s active site to respond selectively to RNA rather than DNA, effectively creating a molecular switch.
##3. Highly Selective Transcript Knockdown: >90% Down‑regulation with Minimal Off‑Target Activity In a variety of cellular assays, including human cell lines, the ΨDNA‑Cas12 system suppressed disease‑relevant transcripts with greater than 90% efficiency. Importantly, the pervasive cytotoxicity and nonspecific RNA degradation observed with Cas13 were absent. Off‑target effects were reduced to baseline levels, demonstrating that the system can pinpoint and silence the intended target within the complex cellular RNA milieu.
##4. The Dawn of Safe, Reversible RNA Programming without Nonspecific Toxicity The significance of this work lies in expanding the scope of gene therapy from DNA editing to safe, reversible RNA control. By leveraging the already validated delivery platforms for Cas12 (e.g., AAV, LNP) and simply swapping the guide to a ΨDNA format, the approach offers limitless commercial and clinical potential. It revives the RNA interference and editing market, which had been threatened by collateral cleavage toxicity, and sets a new clinical benchmark for precision transcriptomics.
Nature Biotechnology, Published online: 15 May 2026. DOI: 10.1038/s41587-026-03129-w
Summary: This study introduces a programmable RNA-targeting strategy using engineered ΨDNA guides in complex with Cas12 nucleases. By bypassing the notorious collateral cleavage toxicity inherent to Cas13 systems, the ΨDNA-Cas12 complex achieves over 90% transcript knockdown efficiency with exceptional specificity in eukaryotic cells. This framework repurposed a traditional DNA-cutting machinery into a high-fidelity RNA modulation tool, opening new avenues for safer transcriptomic therapies.
This dataset presents a next‑generation RNA control tool that eliminates toxicity through a molecular‑biological innovation termed ‘substrate reprogramming.’ By leveraging the existing hardware infrastructure of the AAV gene‑therapy market (e.g., AAV, LNP) and merely swapping the software component (the guide), it enables protocols that target solid tumors and hereditary RNA diseases. Consequently, it constitutes a high‑value core dataset for drug‑pipeline screening algorithms and AI‑driven guide‑design optimization platforms.